karppaus.infon arkistoitu foorumi

Suositun laihdutuslääkkeen Ozempicin kerrotaan tuovan ikäviä ulkonäköhaittoja. Niitä käyttävät kertovat roikkuvista, pieniksi tai hyvin suuriksi jääneistä rinnoista. Vaikutukselle on annettu nimikin: ”Ozempic-rinnat”...

At six months’ follow-up, the team looked at the results from 180 of the patients. The average change to HbA1c was −0.68%, while the average weight loss was 2.63 kg.

Weight-loss drug Ozempic linked to eye condition that can cause blindness in new study

Popular weight-loss jabs Ozempic and Wegovy have been linked to an eye condition that can cause blindness, according to a new study.

People with diabetes prescribed semaglutide (sold under the brand names Wegovy and Ozempic) were more than four times more likely to be diagnosed with a condition called non-arteritic anterior ischemic optic neuropathy (Naion).

Meanwhile, people who were overweight or obese and prescribed the drugs were more than seven times as likely to develop the condition as those on other weight-loss medicines.

Naion, which is uncommon, occurs from a lack of sufficient blood flow to the optic nerve.

People typically suffer sudden vision loss in one eye, without any pain, and patients often notice the issue on waking up.

There are no current treatments for Naion and vision often does not improve.

Common weight loss drugs linked to higher risk of vision loss

Tuoreessa tutkimuksessa on käynyt ilmi, että diabeetikoilla, jotka käyttivät semaglutidilääkitystä, diagnosoitiin harvinainen sokeutta aiheuttava sairaus, NAION, yli neljä kertaa todennäköisemmin kuin niillä, joilla kyseistä lääkettä ei ollut käytössä, kertoo CNN.

Samassa tutkimuksessa ilmeni myös, että niillä ylipainoisilla ja lihavilla, jotka käyttivät semaglutidilääkitystä lihavuuden hoitoon, oli yli seitsemän kertaa todennäköisempää sairastua kyseiseen sairauteen kuin niillä, jotka eivät käyttäneet lääkettä.

DIABETESLÄÄKE semaglutidin käyttö voi lisätä riskiä sairastua näköhermon anterioriseen neuropatiaan (naion), selviää Harvardin yliopiston tutkimuksesta.

The European Medicines Agency issued new recommendations Friday, saying patients who take GLP-1 drugs like Ozempic, Wegovy, Mounjaro and Zepbound should inform their doctors ahead of surgery to minimize the risk of adverse respiratory events potentially caused by the drugs.

Suomessa yli 160 haittavaikutusilmoitusta.

https://www.iltalehti.fi/terveysuutiset ... f49e101007

In partnership with market research firm Beresford Research, we asked 300 primary care providers, endocrinologists, and obesity-certified specialists across the U.S. what they really think about these so-called “miracle” drugs for weight loss.

Overall, we found that physicians are doubtful about the potential for GLP-1s to drive long-term weight loss, lower costs, or make any real impact on the obesity epidemic. Per the doctors surveyed:

-GLP-1s are not sustainable. The majority (73%) of providers do not believe GLP-1 drugs are sustainable beyond 2-3 years, and none think they should be taken for life.

-GLP-1s are over-prescribed, and lifestyle approaches should be the first line of defense. Three-quarters feel GLP-1s are being prescribed too easily and more than they should. Instead, 94% of providers feel strongly that patients should try a lifestyle program before a weight loss drug.

-More oversight is needed. Almost all physicians (97%) believe prior authorization helps ensure only patients with true clinical need can access GLP-1s for weight loss and obesity. Nearly two-thirds (64%) believe that more provider oversight is necessary.

-Unrealistic expectations are common. Two-thirds of providers report that most or all patients are not properly educated on GLP-1s. More than 80% of doctors believe patients have unrealistic expectations about the outcomes, durability, and side effects of GLP-1s.

-Top concerns with using GLP-1s for weight loss are predatory pharmaceutical marketing practices (70%), supply chain issues for diabetes patients (63%), and prescribing behavior.

-GLP-1s will increase health inequities. A whopping 94% feel that GLP-1s will negatively impact disadvantaged groups, who have less access to these drugs.

-GLP-1s are poised to grow exponentially while increasing healthcare costs. Nearly 9 in 10 providers expect GLP-1 growth to at least double this year; over half expect GLP-1 growth to more than triple. Two-thirds (68%) report being considerably concerned about rising costs and 94% believe GLP-1s will increase the cost of healthcare overall.